Interview with Yong Taek Chang, Founder, Shin Poong Pharm
Could you please introduce Shinpoong, which you founded in 1962, and mention the main milestones of this unique company in the Korean pharmaceutical industry? I founded Shinpoong in a very…
Bioneer Corp., founded in 1992 as the first bio-venture in South Korea, is moving forward to a full-fledged molecular biotechnology company on the strength of the R&D infrastructure and intellectual properties.
Since beginning the home production of synthetic oligonucleotides and PCR enzymes with its proprietary technology for the first time in Korea, Bioneer has continuously built up expertise in molecular diagnostics and RNAi therapeutics. Bioneer is currently providing total solutions for molecular diagnostics in various disease areas through an integrated platform of reagents, instruments and analysis software. Bioneer’s SAMiRNA™ is a new paradigm of RNAi therapeutics in terms of being a much more efficient carrier compared to the conventional methods to deliver siRNA to the inside of a target cell.
Bioneer has vertically integrated genomic technology-based businesses, which provides competitive advantages in the market such as price competitiveness, product development efficiency and a high level of control. Today, Bioneer is operating businesses in the following three domains: Research-use products in genomics, biotechnology, molecular biology, etc.; Molecular diagnostic reagents, instruments and software; New development based on RNAi.
Contact details
Webpage: www.bioneer.com
Address: 8-11, Munpyeongseo-ro, Daedeok-gu, Daejeon 306-220, Republic of Korea
Tel: +82-42-930-8777
Fax: +82-42-930-8688
Email: sales@bioneer.com
Could you please introduce Shinpoong, which you founded in 1962, and mention the main milestones of this unique company in the Korean pharmaceutical industry? I founded Shinpoong in a very…
Novartis’ Head Office in Basel, Switzerland as well as several prior international assignments in Asia and Europe. What do you find as the most interesting particularities of the pharmaceutical sector…
Please introduce the Korean Food and Drug Administration (KFDA) and its main health-related responsibilities within the Korean government… The KFDA’s main duty is to cooperate and support with domestic and…
How would you rate South Korea’s healthcare system when compared to regional peers and other OECD countries – main strong points and room for improvement? Since the introduction of the…
You have a very long track record working with Novo Nordisk in Asia. What is your perspective on the Diabetes explosion that has been taking place in this part of…
Already an economic powerhouse thriving on export-driven industries such as electronics, automotive and ship-building, South Korea is now looking to boost its potential in the life sciences and to…
Over the last several years we have seen a shift in clinical research from traditional healthcare markets to Asia. How do you see this trend evolving in the coming years?…
See our Cookie Privacy Policy Here